| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 6
| Issue : 6 | Page : 240-249 |
|
|
Depression in pulmonary arterial hypertension and interstitial lung diseases
Sameer Verma1, Jose Cardenas-Garcia1, Prasanta R. Mohapatra2, Arunabh Talwar1
1 Department of Pulmonary, Critical Care and Sleep Medicine, North Shore - Long Island Jewish Health System, New York, USA
2 Department of Pulmonary Medicine, All India Institute of Medical Sciences, Sijua, Bhubaneswar, Odisha, India
Correspondence Address:
Arunabh Talwar
North Shore-LIJ Health System Pulmonary, Critical Care and Sleep Medicine, 410 Lakeville Rd. New Hyde Park, New York 11040, USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1947-2714.134368
|
|
|
Advanced lung diseases such as pulmonary arterial hypertension (PAH) and interstitial lung diseases (ILD) are chronic diseases that cause significantly high morbidity and mortality. As a result, patients can undergo some psychological changes leading to a poor quality of life and depression. Diagnosis of depression is often obscured because fatigue and apathy, two common symptoms of depression, frequently overlap with PAH and ILD. Healthcare providers are sometimes reluctant to ask or mistakenly believe that these symptoms are part of the ongoing disease process, rather than a serious condition like depression. Screening tools are available for physicians to be well positioned in recognizing clinical depression in PAH and ILD. A MedLine/PubMED search was performed identifying all relevant articles with "PAH", "ILD", "screening tools" and/or "Depression" in the title. The aim of this review is to provide a brief description of some of the instruments used to screen patients and classes of psychotropic medications accessible to physicians. While pulmonary rehabilitation programs can have a positive impact on patients, physicians should also utilize cognitive behavioral therapy (CBT) as part of regular care. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
